PharmaEngine, Inc. (TPEX:4162)

Market Cap	8.18B -50.5%
Revenue (ttm)	911.42M -63.9%
Net Income	387.64M -77.9%
EPS	2.69 -77.9%
Shares Out	143.68M
PE Ratio	21.15
Forward PE	20.62
Dividend	6.00 (10.54%)
Ex-Dividend Date	Aug 13, 2025

Volume	300,429
Average Volume	413,197
Open	58.30
Previous Close	56.90
Day's Range	56.70 - 58.30
52-Week Range	56.30 - 107.50
Beta	0.15
RSI	33.85
Earnings Date	May 12, 2026

About PharmaEngine

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 44
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4162

Financial Performance

In 2025, PharmaEngine's revenue was 911.42 million, a decrease of -63.88% compared to the previous year's 2.52 billion. Earnings were 387.64 million, a decrease of -77.86%.